Bispecific CAR T-Cells Show High Response in Extramedullary Multiple Myeloma

Addressing Extramedullary Multiple Myeloma with Advanced CAR T-Cell Strategies

Relapsed or refractory multiple myeloma (RRMM) remains an incurable malignancy, and outcomes are particularly poor for patients who develop extramedullary disease (EMD), where myeloma proliferates outside the bone marrow [1, 2, 3]. While chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA) have produced overall response rates above 80% in the broader RRMM population, their efficacy is diminished in patients with EMD [4, 5, 2, 6, 3]. This treatment gap has prompted investigation into more robust strategies, such as bispecific CAR T-cells designed to engage two separate tumor antigens simultaneously. By targeting both BCMA and G protein-coupled receptor class C group 5 member D (GPRC5D), a new study sought to determine if such a dual-targeted approach could overcome the resistance seen in this high-risk subgroup [4, 7, 8, 9].

Dual-Targeting CAR T-Cells for a High-Risk Population

To address the urgent need for effective treatments in multiple myeloma with extraosseous spread, investigators designed a therapy to counteract potential antigen escape, a common mechanism of resistance. They developed a bispecific CAR T-cell construct targeting both BCMA and GPRC5D, two antigens highly expressed on myeloma cells. The hypothesis was that engaging two targets would create a more potent and durable anti-tumor effect, particularly in the aggressive context of extramedullary disease.

This strategy was evaluated in a single-arm, open-label, phase 2 trial that enrolled 37 patients with RRMM and confirmed extraosseous EMD. This cohort represents a population with a significant unmet clinical need. Following lymphodepleting chemotherapy, each participant received a single infusion of the anti-BCMA/GPRC5D bispecific CAR T-cells at a dose of 2.0×10⁶ cells per kilogram, allowing for a focused assessment of this therapy's activity and safety in a uniformly high-risk group.

Significant Clinical Responses Observed

The dual-targeting CAR T-cell therapy demonstrated substantial clinical activity in this difficult-to-treat population over a median follow-up of 10.1 months (interquartile range 6.4–19.1). An overall response was achieved in 36 of 37 patients (97%), a rate that also translated into deep molecular remissions. Specifically, all 36 responding patients (97% of the total cohort) also achieved measurable residual disease (MRD) negativity, indicating clearance of myeloma cells below the threshold of standard detection. Among these, 16 patients (43%) reached a stringent complete response (sCR), the deepest category of clinical remission.

While the responses were profound, their durability varied. The median progression-free survival (PFS) was 5.8 months (95% confidence interval [CI]: 2.2–9.4). However, a key positive indicator for this high-risk group was that the median overall survival (OS) was not reached during the follow-up period, suggesting that a majority of patients were still alive at the time of analysis.

Manageable Safety Profile

The safety evaluation revealed a predictable and manageable toxicity profile, consistent with other potent cellular therapies. The most common grade 3 or worse adverse events were hematologic. Notably, all 37 patients (100%) experienced grade 3 or higher hematologic toxicities (excluding lymphopenia). This degree of myelosuppression is an expected consequence of the preparative lymphodepletion regimen and the inflammatory response, and it is typically managed with supportive care, including transfusions and growth factors.

In contrast, rates of specific CAR T-cell-related toxicities were lower and less severe. Cytokine release syndrome (CRS) occurred in 27 patients (73%), but all cases were grade 1 or 2, indicating no instances of severe, life-threatening CRS. Immune effector cell-associated neurotoxicity syndrome (ICANS) was infrequent, affecting only two patients (5%). One case was grade 1, and the other was grade 3. The authors concluded that this safety profile, characterized by universal but expected hematologic toxicity and low rates of severe CRS and ICANS, was acceptable for this patient population.

Clinical Implications and Ongoing Research

For clinicians managing RRMM, these findings provide evidence for a potential new therapeutic option for patients with extraosseous disease, a group for whom standard treatments often fail. The 97% overall response rate and 43% stringent complete response rate in this specific high-risk population are clinically meaningful. While the median PFS of 5.8 months underscores the challenge of achieving durable remission, the fact that median OS was not reached suggests the therapy may extend survival for a subset of these patients, providing a crucial bridge or definitive treatment where few alternatives exist.

The manageable safety profile is also a key takeaway. The absence of grade 3 or higher CRS and the low 5% incidence of ICANS suggest that this potent therapy can be administered without the rates of severe inflammatory toxicity seen with some other CAR T-cell products. The trial is ongoing and registered with ClinicalTrials.gov as NCT05509530. Future data from this study will be critical for clarifying the long-term durability of responses, defining the ultimate impact on overall survival, and positioning this bispecific CAR T-cell therapy within the treatment algorithm for high-risk multiple myeloma.

References

1. Vegivinti C, Vojjala N, Santhi JLA, et al. Overall response rates and progression free survival rates of bispecific antibodies vs CAR-T in the treatment of extramedullary disease and high-risk cytogenetics in relapsed multiple myeloma: A systematic review and meta-analysis. Blood. 2025. doi:10.1182/blood-2025-7599

2. Zhang L, Shen X, Yu W, et al. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.. Annals of medicine. 2021. doi:10.1080/07853890.2021.1970218

3. Li Y, Li M, Li J, et al. Efficacy and safety of BCMA-directed CAR T-cell therapy in extramedullary relapsed or refractory multiple myeloma: a meta-analysis. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1792558

4. Xiang X, He Q, Ou Y, Wang W, Wu Y. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials. Frontiers in Pharmacology. 2020. doi:10.3389/fphar.2020.544754

5. Pereira R, Bergantim R. An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis.. International journal of molecular sciences. 2024. doi:10.3390/ijms25094996

6. Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. International Journal of Medical Sciences. 2021. doi:10.7150/ijms.46811

7. Xu H, Guan C, Xu P, et al. Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Frontiers in Oncology. 2024. doi:10.3389/fonc.2024.1355643

8. Xu X, Dong C, Guo J, et al. Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis.. Frontiers in oncology. 2026. doi:10.3389/fonc.2026.1744250

9. Qiu L, Ren S, He Y, et al. A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease. Blood. 2024. doi:10.1182/blood-2024-210226